Bionano Genomics
BNGO
148 hedge funds and large institutions have $187M invested in Bionano Genomics in 2022 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 43 increasing their positions, 51 reducing their positions, and 22 closing their positions.
50% more call options, than puts
Call options by funds: $5.32M | Put options by funds: $3.54M
1% less funds holding
Funds holding: 149 → 148 (-1)
5% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 22
1.17% less ownership
Funds ownership: 26.3% → 25.12% (-1.2%)
16% less repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 51
18% less capital invested
Capital invested by funds: $228M → $187M (-$40.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Allianz Asset Management
Munich,
Germany
|
+$2.78M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.36M |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
+$1.3M |
| 4 |
State Street
Boston,
Massachusetts
|
+$1.18M |
| 5 |
Morgan Stanley
New York
|
+$1.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$6.08M |
| 2 |
EGM
Engineers Gate Manager
New York
|
-$1.96M |
| 3 |
Squarepoint
New York
|
-$1.55M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$1.27M |
| 5 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$1.24M |
BNGO Hedge Fund Activity: Q1 2022 in Review
148 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Bionano Genomics (BNGO) for Q1 2022, worth a combined $187M — down 18% from $228M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of BNGO and 21 opened new positions — a net loss of 1 holder — while 51 trimmed existing stakes and 43 added.
The largest buyer was Allianz Asset Management, opening a new position worth an estimated $2.78M. The largest seller was Citadel Advisors, cutting an estimated $6.08M.
- 148 institutional investors held Bionano Genomics (BNGO) as of Q1 2022, down from 149 in Q4 2021.
- Funds reported $187M of Bionano Genomics stock for Q1 2022, down 18% quarter-over-quarter.
- 21 funds opened new Bionano Genomics positions in Q1 2022 and 22 closed out, a net change of -1 holder.
- The largest Bionano Genomics buyer in Q1 2022 was Allianz Asset Management, an estimated $2.78M added.
- The largest Bionano Genomics seller in Q1 2022 was Citadel Advisors, an estimated $6.08M sold.
Based on aggregated 13F filings for Q1 2022.